Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A first-in-human phase 1 Study of cbx-250, a TCR-mimetic bispecific T cell engager targeting CG1/ HLA-a*02:01 in patients with relapsed or refractory AML, HR-MDS, or CMML (CROSSCHECK-001) (Trial in Progress)

Brian Ball, Stephen Strickland, Briggs Morrison, John DiPersio, Shaliny Kushwaha, Benjamin Lee, Rachel Ghiraldi, Kevin Cho, John Goll, David Sallman, Ghayas Issa

Blood (2025) 146 (Supplement 1): 3430.

https://doi.org/10.1182/blood-2025-3430

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Blood (2025) 146 (Supplement 1): 766.

https://doi.org/10.1182/blood-2025-766

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Blood (2025) 146 (Supplement 1): 764.

https://doi.org/10.1182/blood-2025-764

Published: 2025

Journal Articles

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Blood (2025) 146 (Supplement 1): 763.

https://doi.org/10.1182/blood-2025-763

Published: 2025

Journal Articles

Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Nosha Farhadfar, Stephen Strickland, Ashish Bajel, Alireza Eghtedar, Brian Garrison, Rochelle Emery, Kanya Rajangam, Gary Schiller, Farhad Ravandi

Blood (2025) 146 (Supplement 1): 1044.

https://doi.org/10.1182/blood-2025-1044

Published: 2025

Journal Articles

A phase 1 dose escalation and dose optimization study to evaluate the preliminary safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity profile of AUTX703 in participants with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6952.

https://doi.org/10.1182/blood-2025-6952

Published: 2025

Journal Articles

Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia

Sangeetha Venugopal, Neil Palmisiano, Guru Subramanian Guru Murthy, Theodore Braun, Alex Ambinder, Jonathan Feld, Sharad Khurana, Stephen Strickland, Rajneesh Nath, Konstantinos Sdrimas, Raquel Ruiz, Beatriz Bruno, Sonia Gutierrez, Douglas Faller, Ana Limon, Amir Fathi

Blood (2025) 146 (Supplement 1): 5197.

https://doi.org/10.1182/blood-2025-5197

Published: 2025

Journal Articles

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

Eytan Stein, Alice Mims, Zhuoer Xie, Gabriel Mannis, Justin Watts, Farhad Ravandi, Gary Schiller, Brian Ball, Hongtao Liu, Jessica Altman, Eunice Wang, J. Jean Cui, Jihao Zhou, Zachary Zimmerman, Stephen Strickland

Blood (2025) 146 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2025-1655

Published: 2025

Journal Articles

Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action

Muharrem Muftuoglu, Enping Hong, Nosha Farhadfar, Stephen Strickland, Ashish Bajel, Alireza Eghtedar, Gary Schiller, Mahesh Basyal, Li Li, Lawrence Naitmazi, Rochelle Emery, Timothy Lu, Brian Garrison, Kanya Rajangam, Farhad Ravandi, Michael Andreeff

Blood (2025) 146 (Supplement 1): 5921.

https://doi.org/10.1182/blood-2025-5921

Published: 2025

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Blood (2022) 139 (23): 3366–3375.

https://doi.org/10.1182/blood.2021011583

Published: 2022

Includes: Supplemental data

Journal Articles

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.

Guillermo Garcia-Manero, MD, Selina Luger, MD, Parameswaran Venugopal, MD, Lori J. Maness, MD, Meir Wetzler, MD, Jessica Altman, MD, David F. Claxton, M.D., Stephen Strickland, MD, Stefan Faderl, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 1758.

https://doi.org/10.1182/blood.V114.22.1758.1758

Published: 2009

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A first-in-human phase 1 Study of cbx-250, a TCR-mimetic bispecific T cell engager targeting CG1/ HLA-a*02:01 in patients with relapsed or refractory AML, HR-MDS, or CMML (CROSSCHECK-001) (Trial in Progress)

Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Promising results from an ongoing Phase I multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

A phase 1 dose escalation and dose optimization study to evaluate the preliminary safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity profile of AUTX703 in participants with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes

Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only